Non-alcoholic Steatohepatitis Treatment Market Analysis

Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid, Lanifibranor, Semaglutide, Resmetirom, Aramchol, Others)

The vitamin E and pioglitazone segment in the non-alcoholic steatohepatitis treatment market is estimated to gain the largest revenue share in the year 2037. The growth of the segment can be attributed to the increasing effectiveness of vitamin E and pioglitazone in treating NASH patients. In an experiment of using pioglitazone for treating 52 NASH patient with type-II diabetes and 49 with prediabetes. The result showed that compared to 46% of patients without diabetes, 48% of type 2 diabetes patients achieved the primary outcome. Compared to 26% of people without type 2 diabetes, resolution of NASH was achieved in 44% of those patients. On the other hand, few experiments have shown that a dose of 800 IU per day of vitamin E is beneficial for active NASH adult patients without any form of diabetes.

Distribution Channel (Hospital Pharmacies, Retail & Specialty Pharmacies)

Non-alcoholic steatohepatitis treatment market from the retail & specialty pharmacies segment is expected to garner a significant share in the year 2037. NASH is an chronic disease that forces patient to be on medication for a very long period, that boost the sales of NASH drugs from the retail pharmacies. NASH therapeutic should be continuously received by the patient otherwise it can lead to severe issues, such as liver failure, liver transplantation, and even liver cancer. In the cases of liver cancer, NASH is combined with liver cancer therapeutics which reduces its efficacy. Therefore, it is important to continue the course of drugs for NASH. The segment growth is major attributed to homecare facilities that are connected to retail pharmacies, which in turn boost the demand for off-label drugs. Few pharmaceutical corporations have indicated that the total medication market for NASH is worth around USD 35 Billion.

Our in-depth analysis of the global NASH treatment market includes the following segments:

Distribution Channel

Hospital Pharmacies
Retail & Specialty Pharmacies

Drug Type

Vitamin E and Pioglitazone
Obeticholic Acid
Lanifibranor
Semaglutide
Resmetirom
Aramchol
Others

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of non-alcoholic steatohepatitis treatment is estimated at USD 7.07 billion.

The non-alcoholic steatohepatitis treatment market size was valued at USD 6.16 billion in 2024 and is expected to cross USD 50.5 billion by the end of 2037, expanding at more than 18.2% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of NAFLD will drive the market growth.

North America industry is projected to hold the largest revenue share of 40% by 2037, backed by rising cases of non-alcoholic fatty liver diseases in the region.

The major players in the market include Intercept Pharmaceuticals, Inc., Pfizer, Inc., Inventiva, Galmed Pharmaceuticals Ltd., Novo Nordisk A/S, Madrigal Pharmaceuticals, Galectin Therapeutics, NGM Biopharmaceuticals, Brsitol-Myers Squibb Company, Can Fite, Zydus Lifesciences Ltd., Mitsubishi Chemical Group Corporation.

Non-alcoholic Steatohepatitis Treatment Market Analysis